<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05108883</url>
  </required_header>
  <id_info>
    <org_study_id>IDEAL+ Study</org_study_id>
    <nct_id>NCT05108883</nct_id>
  </id_info>
  <brief_title>Risk Stratification Using Midregional Proadrenomedullin in the ED</brief_title>
  <official_title>IDEntifying pAtients With Suspicion of Infection in the ED Who Have Low Disease Severity Using Midregional Proadrenomedullin (MR-proADM) - Pivotal Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brahms AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brahms AG</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Emergency departments (ED) are becoming increasingly over-crowded, with patients facing&#xD;
      prolonged waiting times. Therefore, a safe and rapid assessment that identifies patients with&#xD;
      low severity that could be treated as outpatients is essential for improving the workflow&#xD;
      within the ED.&#xD;
&#xD;
      The rationale of this IDEAL+ study is to safely decrease the number of hospital admissions&#xD;
      through identification of low risk patients with the biomarker MR-proADM. This will has&#xD;
      already been tested in the IDEAL - pilot study and results should be confirmed with this&#xD;
      IDEAL+ study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of out-patients re-presenting to the ED</measure>
    <time_frame>5 days</time_frame>
    <description>Number of out-patients re-presenting to the ED</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">452</enrollment>
  <condition>Patients Presenting With Suspicion of Infection to the ED</condition>
  <arm_group>
    <arm_group_label>standard care arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>decision whether a patient will be hospitalized or be treated as out-patient is based on routine clinical assessment and usual protocols</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MR-proADM guided arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>decision whether a patient will be hospitalized or be treated as out-patient is based on routine clinical assessment, usual protocols and MR-proADM levels</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MR-proADM KRYPTOR</intervention_name>
    <description>MR-proADM ≤ 0.87 nmol/L together with routine clinical evaluation identifies patients with low disease severity who do not need to be hospitalized</description>
    <arm_group_label>MR-proADM guided arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Consecutive patients presenting to the ED with suspicion of infection&#xD;
&#xD;
          2. Age ≥18 years&#xD;
&#xD;
          3. Written Informed Consent obtained&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with SARS-COV-2 infection&#xD;
&#xD;
          2. Recent major trauma or surgery&#xD;
&#xD;
          3. End stage renal failure requiring dialysis&#xD;
&#xD;
          4. Terminal disease and/or very severe medical co-morbidity where death has to be&#xD;
             expected in the next 6 months, e.g. due to malignancy, cardiac, renal or hepatic&#xD;
             failure&#xD;
&#xD;
          5. Patients whose source of infection always requires hospital admission or never&#xD;
             requires hospital admission.&#xD;
&#xD;
          6. Patients who cannot be discharged for other than medical reasons&#xD;
&#xD;
          7. Patient participates in any other interventional clinical trial&#xD;
&#xD;
          8. Patients with active abusive drug use&#xD;
&#xD;
          9. Pregnant or lactating women&#xD;
&#xD;
         10. Patients who are institutionalized by official or judicial order&#xD;
&#xD;
         11. Dependents of the sponsor, the CRO, the study site or the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ines Rudolph, PhD</last_name>
    <phone>00493302883</phone>
    <phone_ext>0</phone_ext>
    <email>ines.rudolph@thermofisher.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefan Ebmeyer, MD</last_name>
    <phone>00493302883</phone>
    <phone_ext>0</phone_ext>
    <email>stefan.ebmeyer@thermofisher.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan González del Castillo, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 18, 2021</study_first_submitted>
  <study_first_submitted_qc>November 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

